SCHEMBL20119892

SCHEMBL20119892

Fc1c[nH]c2nc(Cl)nc(NCc3ccncn3)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH3 Q9ULD8 1/20 0.43
KCNA5 P22460 2/20 0.38
PIM1 P11309 2/20 0.38
JAK2 O60674 1/20 0.38
IGF1R P08069 1/20 0.38
SRC P12931 1/20 0.38
CSNK2A2 P19784 1/20 0.38
JAK1 P23458 1/20 0.38
CCNE1 P24864 1/20 0.38
CDK2 P24941 1/20 0.38
TYK2 P29597 1/20 0.38
FLT4 P35916 1/20 0.38
FLT3 P36888 1/20 0.38
MAP3K8 P41279 1/20 0.38
CSNK1A1 P48729 1/20 0.38
GSK3B P49841 1/20 0.38
JAK3 P52333 1/20 0.38
PLK1 P53350 1/20 0.38
CSNK2A1 P68400 1/20 0.38
CDK5 Q00535 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119909 0.89 CDK2 (0.39) KCNH3KCNA5PIM1JAK2IGF1R
SCHEMBL20119730 0.87 PIM1 (0.38) KCNH3KCNA5PIM1JAK2IGF1R
SCHEMBL20119669 0.84 LRRK2 (0.48) KCNH3KCNA5PIM1JAK2IGF1R
SCHEMBL20119362 0.82 PDE5A (0.40) KCNH3CDK2PDE2A
SCHEMBL20119422 0.80 KCNH3 (0.41) KCNH3KCNA5PIM1JAK2IGF1R
SCHEMBL20119640 0.78 KCNH3 (0.40) KCNH3KCNA5PIM1JAK2IGF1R
SCHEMBL20119693 0.78 KCNH3 (0.40) KCNH3KCNA5PIM1JAK2IGF1R
SCHEMBL20119563 0.74 HRH4 (0.36) PIM1IGF1RMAP3K8PTK2DYRK1A
SCHEMBL17933806 0.74 PLK4 (0.41) KCNH3KCNA5PIM1JAK2IGF1R
SCHEMBL20119664 0.74 KCNH3 (0.38) KCNH3KCNA5PIM1JAK2IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 KCNH3 3654/4885KCNA5 4283/4885PIM1 3958/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 KCNH3 3654/4885KCNA5 4283/4885PIM1 3958/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 KCNH3 3654/4885KCNA5 4283/4885PIM1 3958/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 KCNH3 3654/4885KCNA5 4283/4885PIM1 3958/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 KCNH3 3654/4885KCNA5 4283/4885PIM1 3958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.